Tag: outcome-based pricing

New Health Secretary Offers Bold Vision for Reform. But the Devil’s in the Details. | The Heritage Foundation

New Health Secretary Offers Bold Vision for Reform. But the Devil’s in the Details. | The Heritage Foundation

The root problem is that health care “prices” are not really prices, in the conventional economic sense, reflecting the direct collision between the forces of consumer demand and provider supply in anything resembling a real market. They are complex, negotiated payment agreements that take place within a sector of the economy, dominated by third-party, corporate, […]

After a decade of its proposal, DoP still struggling on pricing of patented drugs | Pharmabiz.com

After a decade of its proposal, DoP still struggling on pricing of patented drugs | Pharmabiz.com

The issue of pricing of patented drugs dates back to early 2007 when the DoP initiated steps to frame a method to make sure that the drugs patented abroad remain affordable as and when the multinational companies launch them in India. The DoP had held a series of meetings of the concerned parties and sought […]

Sensible pricing helps GSK in India, says CEO | Times of India

Sensible pricing helps GSK in India, says CEO | Times of India

Mumbai: At a time when the government is planning to dismantle the drug pricing regulator, NPPA, and delink price control from essential medicines, one of the largest companies in the world, GlaxoSmithKline, has rallied around the country’s regulatory regime. Saying “India should be concerned about pricing” to ensure that its people “get access to decent […]

Mylan seeks FDA approval for biosimilar Herceptin copy | FierceBiotech

Mylan seeks FDA approval for biosimilar Herceptin copy | FierceBiotech

Other companies are close behind. South Korea’s Celltrion filed for approval in Europe shortly after Mylan, as did its compatriot Samsung Bioepis. Amgen ($AMGN) and Allergan ($AGN) posted Phase III data on their contender within six weeks of Biocon and Mylan. Pfizer ($PFE) is also in the running. The potential for a string of Herceptin […]

Another Drug Company That Raises Prices Like Crazy | Forbes

Another Drug Company That Raises Prices Like Crazy | Forbes

Starting in April, a little-known generic drug company in Philadelphia suddenly raised the price of fluphenazine, a medication used to treat symptoms of certain types of schizophrenia, by 1,650% over a three-month period. The evidence: Prescription tracking firm IMS Health discloses the number of times a medicine is prescribed and the medicine’s gross sales. IMS […]

Pricing and pharma’s reputation, how deep does it go? | Pharma Business Partners

Pricing and pharma’s reputation, how deep does it go? | Pharma Business Partners

Pharma and its appearance have always been an issue of contention. This is particularly the case when references are made to specialized drugs that are used to treat correspondingly specialized conditions at seemingly exorbitant prices. The key focus of this article is not to look at the justification of the industry’s pricing, but to look […]

Most Americans believe prescription drug prices are unreasonable | STAT

Most Americans believe prescription drug prices are unreasonable | STAT

Roughly 8 in 10 Americans believe that prices for prescription drugs are unreasonable and support various ideas to lower costs, such as allowing Medicare to negotiate with drug makers and enforcing price caps on high-priced medicines for certain illnesses such as cancer, according to a new poll from the Kaiser Family Foundation. Moreover, two-thirds of […]

Some Things Were Left Unspoken: Drug Pricing Not Even Mentioned At First Presidential Debate | Benzinga

Some Things Were Left Unspoken: Drug Pricing Not Even Mentioned At First Presidential Debate | Benzinga

Presidential hopefuls Hillary Clinton and Donald Trump covered a lot of important issues during Monday night’s 1.5-hour debate. However, one issue that was not raised was the topic of prescription drug prices. In the past year, Clinton has specifically called out Valeant Pharmaceuticals Intl Inc VRX  and Mylan NV NASDAQ: MYL by name for their price […]

Govt seeks views on pricing patented drugs | Livemint

Govt seeks views on pricing patented drugs | Livemint

One of the limiting factors is that currently price regulations of patented drugs are the exception and not the norm. Only one compulsory licence has been issued till date in India—to domestic generic drug maker Natco for Bayer AG’s anti-cancer drug Nexavar—which resulted in a 97% price reduction. As per the provisions of compulsory licensing […]

PCMA: ‘It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing’ | Street Insider

PCMA: ‘It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing’ | Street Insider

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on Mylan’s EpiPen price hikes and attacks in the press on payers and pharmacy benefit managers (PBMs): “It was a mistake for Mylan to adopt the failed PR strategy used unsuccessfully by Valeant and Turing. It’s not credible to assert that […]